Fate Therapeutics CMO Dr. Wayne Chu resigns effective July 14, 2023

FATE THERAPEUTICS INC

Dr. Yu-Waye (Wayne) Chu, Chief Medical Officer, resigns to pursue another opportunity.
Resignation effective July 14, 2023; no disagreement with company operations or policies.
No replacement named; CEO J. Scott Wolchko signed the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Yu-Waye (Wayne) Chu

Chief Medical Officer

FATE · FATE THERAPEUTICS INC

Effective: 2023-07-14
Filed: June 8, 2023, 7:59 PM ET

Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. (the “Company”) that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yu-Waye (Wayne) Chu departed as Chief Medical Officer at FATE THERAPEUTICS INC.

Action: resign
Role: Chief Medical Officer

Exact text from the filing

Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. (the “Company”) that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity.

View on SEC.gov

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-027007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.